Targeted DNA sequencing on a cohort of Poor Risk AML samples

Targeted sequencing on a cohort of 57 samples from the Barts Health NHS Trust (London) harbouring poor-risk cytogenetic aberrations including -7/del(7), -5/del(5), KMT2A rearrangements (other than t(9;11)), t(6;9), inv(3), -17/del(17) and complex karyotypes (= 3 chromosomal aberrations). Library Preparation was carried using the TruSight Myeloid Sequencing Panel. Reads were sequenced with a NextSeq 500.

本研究对来自伦敦巴特健康国民保健信托基金（Barts Health NHS Trust）的57例队列样本开展靶向测序，该队列样本携带有不良风险的细胞遗传学异常，涵盖-7/7号染色体缺失（-7/del(7)）、-5/5号染色体缺失（-5/del(5)）、KMT2A重排（排除t(9;11)易位）、t(6;9)易位、3号染色体倒位（inv(3)）、-17/17号染色体缺失（-17/del(17)）以及复杂核型（定义为存在3种及以上染色体异常）。文库制备采用TruSight骨髓测序Panel（TruSight Myeloid Sequencing Panel）完成，测序读段通过NextSeq 500测序平台完成测序。